Trial reportDiabetes research and clinical practice2016
NerveCheck: An inexpensive quantitative sensory testing device for patients with diabetic neuropathy.
Trial report in Diabetes research and clinical practice, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Innovative strategies for diabetic peripheral neuropathy: From clinical management to emerging bioengineering solutions.Bioactive materials · 2026Review
- Promising Biomarkers for Early Diagnosis: Advances in Understanding the Pathogenesis of Diabetic Peripheral Neuropathy.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Review
- Review
- Bibliometric Analysis: Insights Into the Podiatric Medicine Landscape of Diabetic Sensory Peripheral Neuropathy and Genomics.Journal of foot and ankle research · 2025Article
- Screening and monitoring of diabetic polyneuropathy in clinical practice: present and future with connected devices.Frontiers in neurology · 2025Article
- Peripheral Neuropathy in Diabetes Mellitus: Pathogenetic Mechanisms and Diagnostic Options.International journal of molecular sciences · 2023Review
- [Quantitative sensory testing for neuropathic pain and its relevance for physiotherapy].Schmerz (Berlin, Germany) · 2022Review
- Prevalence and risk factors for diabetic peripheral neuropathy, neuropathic pain and foot ulceration in the Arabian Gulf region.Journal of diabetes investigation · 2022Article
- The Role of Neuropathy Screening Tools in Patients Affected by Fibromyalgia.Journal of clinical medicine · 2022Article
- Diabetes Distal Peripheral Neuropathy: Subtypes and Diagnostic and Screening Technologies.Journal of diabetes science and technology · 2022Review
- Prevalence and risk factors for diabetic neuropathy and painful diabetic neuropathy in primary and secondary healthcare in Qatar.Journal of diabetes investigation · 2021Article
- Widespread sensory neuropathy in diabetic patients hospitalized with severe COVID-19 infection.Diabetes research and clinical practice · 2021Article
- Gold Standard for Diagnosis of DPN.Frontiers in endocrinology · 2021Review
- Advances in Screening, Early Diagnosis and Accurate Staging of Diabetic Neuropathy.Frontiers in endocrinology · 2021Review
- Challenges of neuropathic pain: focus on diabetic neuropathy.Journal of neural transmission (Vienna, Austria : 1996) · 2020Review
- Instruments of Choice for Assessment and Monitoring Diabetic Foot: A Systematic Review.Journal of clinical medicine · 2020Review
- VSA-3000: A Quantitative Vibration Sensation Testing Device for Patients With Central Nervous System Injury.Frontiers in neurology · 2020Article
- Early detection of neuropathy in leprosy: a comparison of five tests for field settings.Infectious diseases of poverty · 2017Article
- Association between Hemoglobin Levels and Diabetic Peripheral Neuropathy in Patients with Type 2 Diabetes: A Cross-Sectional Study Using Electronic Health Records.Journal of diabetes research · 2017Article
- NerveCheck for the Detection of Sensory Loss and Neuropathic Pain in Diabetes.Diabetes technology & therapeutics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
aimsSensory neuropathy is central to the development of painful neuropathy, and foot ulceration in patients with diabetes. Currently, available QST devices take considerable time to perform and are expensive. NerveCheck is the first inexpensive ($500), portable QST device to perform both vibration and thermal testing and hence evaluate diabetic peripheral neuropathy (DPN). This study was undertaken to establish the reproducibility and diagnostic validity of NerveCheck for detecting neuropathy.
methods130 subjects (28 with DPN, 46 without DPN and 56 control subjects) underwent QST assessment with NerveCheck; vibration perception and thermal testing. DPN was defined according to the Toronto criteria.
resultsNerveCheck's intra correlation coefficient for vibration, cold and warm sensation testing was 0.79 (95% LOA: -4.20 to 6.60), 0.86 (95% LOA: -1.38 to 2.72) and 0.71 (95% LOA: -2.36 to 3.83), respectively. The diagnostic accuracy (AUC) for vibration, cold and warm sensation testing was 86% (SE: 0.038, 95% CI 0.79-0.94), 79% (SE: 0.058, 95% CI 0.68-0.91) and 72% (SE: 0.058, 95% CI 0.60-0.83), respectively.
conclusionsThis study shows that NerveCheck has good reproducibility and comparable diagnostic accuracy to established QST equipment for the diagnosis of DPN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.